USP2/8-rearranged neoplasms represent a biologically indolent subset of myofibroblastic tumors that can rarely present as intracardiac masses in pediatric patients.
Mesenchymal spindle cell tumors represent a heterogeneous group of neoplasms defined by distinct clinicopathologic features and diverse molecular alterations. While USP6 rearrangements are well-established in nodular fasciitis and related entities, fusions involving other ubiquitin-specific proteases, such as USP2 and USP8, have only recently emerged. Prompted by sporadic reports of USP8 fusions in matrix-rich neoplasms, we aimed to characterize the clinicopathologic and molecular spectrum of USP2/USP8-rearranged mesenchymal tumors. We retrospectively analyzed 19 tumors, evaluating clinical, histopathologic features, immunohistochemical profiles, whole-transcriptome RNA sequencing, and DNA methylation profiling. Nineteen tumors were identified, harboring either USP8 (n=12) or USP2 (n=7) fusions. The cohort included patients aged 3 to 70 years (median: 32). Tumors primarily affected the distal extremities, with the notable exception of 2 intracardiac cases in pediatric patients, harboring USP8 fusions (CBLB::USP8 and SPPL2A::USP8). Histologically, all cases were composed of bland spindle cells arranged in either a myofibromatous or an inflammatory pattern; notably, USP2-fused tumors exhibited an exclusively myofibromatous morphology. Immunohistochemically, SMA was frequently expressed, while desmin, h-caldesmon, ALK, ROS1, panTRK, and CD34 were consistently negative. Transcriptomic analysis demonstrated proximity to myofibroma and nodular fasciitis profiles, rather than forming a distinct USP2/8-specific cluster. No cases showed malignant behavior or recurrence during the available follow-up period. USP2/8-rearranged neoplasms represent a morphologically diverse but biologically indolent subset of myofibroblastic tumors. They exhibit significant overlap with USP6-associated lesions and PDGFR-altered myofibromas. Recognizing these fusions is critical to avoid diagnostic pitfalls and overtreatment, particularly when they present in unusual sites, such as the heart.
Frankel et al. (Wed,) studied this question.